Rheumatoid Arthritis
Conditions
Interventions
It is a randomized and balanced trial in blocks 3 by 3, consisting of 22 women with stable rheumatoid arthritis. All the participants went through all the experimental situations. The experimental des
Other
Sponsors
Universidade Federal dos Vales do Jequitinhonha e Mucuri
Fundação de Amparo à Pesquisa de Minas Gerais
Eligibility
Sex/Gender
Female
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: Women aged 40-60 years, according to the American College of Rheumatology criteria for RA, with at least 6 months of evolution. Some degree of disease activity should be present and pharmacological treatment should be stable for at least 1 month prior to the study, including analgesics, non-steroidal anti-inflammatory drugs, glucocorticoids (must be equal to or less than 15 mg / day prednisone or equivalent). The activity of the disease will be considered with the presence of signs and symptoms that, in the judgment of the physician, would require alteration of the therapy or progression to the more aggressive treatment regimen. Patients should be able to respond to the Health Assessment Questionnaire (HAQ) and global assessment of the patient's treatment and visual analog pain scale (VAS).
Exclusion criteria
Exclusion criteria: Patients who have sensory disorders, active infection, alcoholism or drug abuse, are pregnant or breastfeeding, using anticoagulants or other complementary treatment, presence of any concomitant illness that will prevent them from attending the sessions, presence of any another rheumatic disease, associated or not, which could interfere with the assessment of efficacy and safety and presence of serious complications of RA or that the disease is advanced. During the study, patients will maintain prior drug therapy without adjustments. Participants will be able to use analgesic during the study period if they really feel the need. However, it will be considered as data loss or a new date will be scheduled for data collection. Intra-articular infiltrations or other procedures, such as physical therapy or corrective surgeries, will not be accepted. and will not be able to use analgesics for pain. Intra-articular infiltrations or other procedures, such as physical therapy or corrective surgeries, will not be accepted.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hand grip Strength: Will be measured with the Jamar Dynamometer (Asimow Engineering Co.). The grip strength will be expressed in kilograms-force (Kgf). The patient in the sitting position, with the feet supported on the floor, shoulder adducted and in neutral rotation and the elbow to 90º. Forearm and wrist in position neutral, allowing a slight wrist extension (up to 30º). The patient will press the sequence of 3 times. The grip strength of the hand will result from the average of the results.;Pain: Pain will be assessed using the Visual Analog Pain Scale. The EVA consists of assisting in the measurement of pain intensity in the patient, it is an important tool to verify the evolution of the patient during the treatment and even to each care, in a more reliable way. It is also useful to be able to analyze whether the treatment is being effective, which procedures have performed better, as well as whether there is any deficiency in the treatment, according to the degree of improvement or worsening of the pain. EVA can be used at the beginning and at the end of each service, recording the result always in evolution. In order to use EVA, the caregiver should question the patient about their degree of pain, where 0 means total absence of pain and 10 the maximum level of pain that the patient can bear. ;Active range of flexion-extension of the wrist and the proximal metacarpophalangeal and interphalangeal joints: The ADM will be measured in degrees with a goniometer. The fixed arm of the goniometer will be placed parallel to the longitudinal axis of the proximal end and the movable arm will be positioned parallel to the longitudinal axis of the distal end with the fulcrum at the axis of the joint. The metacarpophalangeal (MF), proximal interphalangeal (PFI), distal interphalangeal (DIF), and wrist of the dominant upper limb joints will be measured.;Upper limb functionality - Sequential Occupational Dexterity Assessment (SODA): developed to assess manual ability and pai | — |
Secondary
| Measure | Time frame |
|---|---|
| Electromyographic activity of the superficial flexor muscle of the dominant upper limb - Surface electromyography (EMG): The activity of the muscles of the MMSS will be recorded using a portable EMG channel (Miotec Equipamentos Biomédicos Ltda, Brazil). The EMG data will be filtered at a frequency of 10-480Hz. Input impedance of 1015 Ohms; analog / digital converter with 16-bit resolution; filters and built-in rechargeable battery and sampling frequency 2000 Hz. Single electromagnetic and differential ground electrodes (Data Hominis Tecnologia Ltda., Brazil) will be used to capture the EMG signals. The preparation of the participants will consist of asepsis of the place of placement of the electrodes, being 2 reference electrodes in the muscular belly of the flexor superficial muscle of the fingers of the dominant hand and a ground wire electrode positioned in the lateral epicondyle of the humerus, according to SENIAM recommendations. ;Neuronal innervation ratio (electromyographic activity of the superficial flexor digitorum muscle / manual grip strength) | — |
Countries
Brazil
Contacts
Public ContactAna Carolina;Ana Cristina Oliveira;Lacerda
Universidade Federal dos Vales do Jequitinhonha e Mucuri;Universidade Federal dos Vales do Jequitinhonha e Mucuri
Outcome results
None listed